16 September 2026 editorial review · Trial
FORWARD: zimislecel (VX-880) and VX-017 stem-cell islets: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Compared current master protocol, NEJM primary report and Vertex/SEC update. AddedVX-017 Part D safety and57 estimated total participants. Separated VX-880: 14 followed / 12 full-dose outcomes from absentVX-017 outcomes; preserved interim, nonprespecified analyses and serious harms. No invented blood-type restriction, dosing milestone or efficacy.
Registry: NCT04786262; RECRUITING; updated 2026-09-01; enrollment 57 (ESTIMATED); results not posted.
Endpoint comparison: Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) (From VX-880 infusion to end of study (at least 5 years)); Parts B and C: Proportion of Participants who are Insulin Independent with Absence of Severe Hypoglycemic Events (SHEs) (1 year after achieving insulin independence (following VX-880 infusion)); Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) (From VX-017 infusion to end of study (at least 5 years)).
Sources for this record: FORWARD: VX-880 and VX-017 (NCT04786262) (registry); Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes (peer-reviewed); Vertex second-quarter 2026 financial results (manufacturer).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.